Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Results from a multicenter, randomized phase 2 trial in China show that adjuvant anti-PD-1 therapy in patients with resected hepatocellular carcinoma with microvascular invasion leads to prolonged recurrence-free survival compared to active surveillance.
In the final report of a phase 1/2 trial evaluating allogeneic CD19-specific CAR-NK cells armored with IL-15 in patients with CD19+ hematologic malignancies, the therapy was shown to be safe and efficacious with distinct cord blood features associated with response.
Analysis of the pivotal phase 3 ZUMA-7 trial identifies tumor gene expression signatures that are uniquely predictive of anti-CD19 CAR T cell response and event-free survival in second-line treatment for patients with relapsed or refractory large B cell lymphoma.
A randomized controlled trial found that functional connectivity-guided approaches to intermittent theta burst stimulation and repetitive transcranial magnetic stimulation both reduced depressive symptoms in patients with moderate to severe treatment-resistant depression over 26 weeks.
In a randomized clinical trial enrolling older people living in a community setting, exergame step training on a computerized mat, but not seated cognitive training, decreased the rate of falls over the course of a year, as compared to a control group provided with an education booklet on healthy aging and fall prevention.
The first report from the Cancer Programme of the 100,000 Genomes Project presents whole-genome sequencing profiles of 13,880 solid tumors spanning 33 cancer types, combined with real-world clinical data, providing insights for precision oncology.
A meta-analysis using the Burden of Proof method reported consistent evidence supporting harmful associations between exposures to secondhand smoke and nine health outcomes.
In a phase 1 trial, a lymph node-targeting mutant KRAS peptide vaccine combined with CpG adjuvant is safe, reduces expression of tumor biomarkers and elicits mutant KRAS-specific T cells in patients with pancreatic cancer and colorectal cancer.
Systematic evaluation of literature in four databases to generate an evidence gap map for noncommunicable disease interventions in children and adolescents shows that over 90% of studies have been done in high-income countries and that evidence for interventions for mental health conditions, obesity and substance misuse is lacking globally.
In this prespecified analysis of the ongoing TORCHLIGHT phase 3 trial, first-line treatment with toripalimab and nab-paclitaxel in patients with advanced triple-negative breast cancer led to significantly longer progression-free survival in the PD-L1-positive population compared to nab-paclitaxel alone.
A neoadjuvant treatment regimen of anti-PD-L1 monotherapy followed by anti-PD-L1 plus chemotherapy was well tolerated and led to a major pathologic response rate of 70% in patients with resectable gastric or gastroesophageal junction adenocarcinoma.
Military veterans with traumatic brain injuries who received treatment with the psychoactive compound ibogaine and magnesium experienced improvements in disability, psychiatric symptoms and cognition.
A real-world retrospective cohort study provides evidence that semaglutide prescription is not associated with higher risks of suicide ideation when compared with other anti-obesity or anti-diabetic medications.
Exploratory ctDNA analyses from the phase 3 INTRIGUE trial indicate that ripretinib may provide benefits in patients with advanced gastrointestinal stromal tumors with KIT exon 11 + 17/18 mutations
In a proof-of-concept randomized trial in schoolchildren from Northern Senegal, artesunate–mefloquine at antimalarial dosage was noninferior to standard-care praziquantel for the treatment of schistosomiasis.
Two-year interim data from an ongoing phase 1/2 trial of the AAV-based gene therapy bidridistrogene xeboparvovec in six patients with limb-girdle muscular dystrophy show a safe profile and preliminary increased expression of the β-sarcoglycan protein.
A deep learning algorithm shows promising performance in predicting progression to diabetic retinopathy in patients, up to 5 years in advance, potentially providing support for medical treatment decisions and indications for personalized screening frequency in a real-world cohort.
A substudy of the CodeBreaK 101 trial, this phase 1b trial testing the KRAS-G12C inhibitor sotorasib with an anti-EGFR antibody shows an acceptable safety profile of this combination and encouraging preliminary clinical efficacy in patients with chemotherapy-refractory colorectal cancer.
Treatment of patients with relapsed or refractory multiple myeloma with a combination of the BCMA-targeting antibody–drug conjugate belatamab mafodotin with dexamethasone and pomlidomide is safe and shows promising preliminary clinical efficacy.